WilmerHale Represents Nuvalent in Public Offering

WilmerHale Represents Nuvalent in Public Offering

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
On October 19, 2023, Nuvalent, Inc., a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, announced the closing of its underwritten public offering of 5,357,143 shares of its Class A common stock, at a price to the public of $56.00 per share. The aggregate gross proceeds to Nuvalent were $281.6 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Nuvalent. J.P. Morgan Securities LLC, Cowen and Company, LLC, Piper Sandler & Co. and BMO Capital Markets Corp. acted as joint book-running managers for the offering. Wedbush Securities Inc. acted as a manager for the offering.

The WilmerHale team advising Nuvalent in its public offering was led by Cynthia Mazareas, Andrea Sorrentino, Katharine Patterson, Matt Kosior and AJ Febles, with assistance from Julie Hogan Rogers, Bruce Manheim, Ben Lobley, Heidi Treiber and Senior Paralegal Mark Devine.
 

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel